Salvato Chiara, Aretini Gianfranco, Serraglia Donatella, Terrazzani Gianni, Debetto Patrizia, Giusti Pietro, Chinellato Alessandro
Office of Pharmaceutical Service, Local Health Authority No 9, Treviso, Italy.
Pharmacol Res. 2003 Jul;48(1):75-82.
A retrospective survey of the opioid prescriptions issued for cancer outpatients (2125) of the Treviso district (Veneto Region, northern Italy) during the time period 1993-2000 was carried out with the specific aims to establish the rate of opioid prescription and verify whether terminally ill outpatients (1697) who had died by the end of December 2000 received adequate opioid prescription, as compared with the Defined Daily Doses (DDDs) of opioids suggested by the World Health Organization (WHO) for a standard population. For both women and men, the maximum rate of opioid prescription was at the age of beyond 90 years. Men were more prescribed than women between 60 and 79 years of age, whereas women were more prescribed than men beyond 90 years. Opioid prescriptions concerned only morphine, buprenorphine, and pentazocine. The Anatomical Therapeutic Chemical (ATC)/DDDs analysis of opioid prescriptions indicated that total opioid use increased about 1.7-fold between 1993 and 1996, mainly because of an increase (55.4%) in morphine prescriptions. Afterwards, total opioid use remained stable, with an estimated mean annual value of 108.2+/-6.4 DDDs/million inhabitants/day. Considering terminally ill outpatients who had died by the end of December 2000, oral morphine turned out to be the most commonly prescribed opioid (64% of patients) and, among the three opioids, pentazocine was more prescribed to older patients. From the comparison between the number of "expected opioid DDDs" (i.e. days for which patients should have been prescribed opioids at the WHO recommended DDDs) and the number of prescribed opioid DDDs (i.e. days for which patients had been offered adequate opioid treatment) for individual patients, it could be estimated that only 38.1% of opioid prescriptions were adequate and a mean of 55.8 DDDs of opioids per patient were not prescribed. The opioid prescription inadequacy increased with the length of time from first prescription to patient death. In addition, a questionnaire investigation, conducted in 2001 among general practitioners of the Treviso district to evaluate their attitudes toward opioid prescribing, evidenced insufficient knowledge of general practitioners in theory and use of opioid analgesics in cancer pain management. A total of 104 (32.5%) general practitioners responded and most of them feared opioid side effects, such as respiratory depression (49.6%), constipation (41.7%), and addiction (8.7%). Furthermore, many of the respondents considered opioids capable of reducing the patient length of life (22.2%) and inappropriate to treat pediatric patients (50.6%). About 44% of the respondents experienced external pressure by relatives of patients against opioid prescription and a majority of them (58.2%) considered the recently revised Italian legislation on opioid prescription ineffective for improving their prescribing pattern. In conclusion, present data show that the vast majority of terminally ill cancer outpatients in the Treviso district received inadequate opioid prescriptions in relation to either drug daily dosage or therapy duration. Misconceptions of general practitioners of the district about opioids could contribute to the inappropriate use of these analgesics in cancer pain management. As far as we know, the ATC/DDD methodology for the opioid prescription analysis used in this survey has not been applied before.
对1993 - 2000年期间意大利北部威尼托大区特雷维索地区2125名癌症门诊患者开具的阿片类药物处方进行了回顾性调查,具体目的是确定阿片类药物处方率,并核实到2000年12月底死亡的晚期门诊患者(1697名)与世界卫生组织(WHO)为标准人群建议的阿片类药物限定日剂量(DDD)相比,是否接受了足够的阿片类药物处方。对于男性和女性,阿片类药物处方率最高的年龄段均超过90岁。60至79岁年龄段男性的处方量多于女性,而90岁以上女性的处方量多于男性。阿片类药物处方仅涉及吗啡、丁丙诺啡和喷他佐辛。阿片类药物处方的解剖治疗学化学(ATC)/DDD分析表明,1993年至1996年期间阿片类药物总用量增加了约1.7倍,主要原因是吗啡处方量增加(55.4%)。此后,阿片类药物总用量保持稳定,估计年均值为108.2±6.4 DDDs/百万居民/天。考虑到2000年12月底前死亡的晚期门诊患者,口服吗啡是最常开具的阿片类药物(64%的患者),且在这三种阿片类药物中,喷他佐辛在老年患者中的处方量更多。通过比较个体患者的“预期阿片类药物DDD数”(即按照WHO推荐的DDD患者应开具阿片类药物的天数)和开具的阿片类药物DDD数(即患者实际接受足够阿片类药物治疗的天数),可以估计只有38.1%的阿片类药物处方是足够的,每位患者平均有55.8 DDDs的阿片类药物未被开具。从首次处方到患者死亡的时间越长,阿片类药物处方不足的情况越严重。此外,2001年对特雷维索地区全科医生进行的问卷调查,以评估他们对阿片类药物处方的态度,结果表明全科医生在癌症疼痛管理中对阿片类镇痛药的理论和使用知识不足。共有104名(32.5%)全科医生回复,他们中的大多数人担心阿片类药物的副作用,如呼吸抑制(49.6%)、便秘(41.7%)和成瘾(8.7%)。此外,许多受访者认为阿片类药物会缩短患者寿命(22.2%)且不适用于治疗儿科患者(50.6%)。约44%的受访者受到患者亲属反对阿片类药物处方的外部压力,其中大多数人(58.2%)认为最近修订的意大利阿片类药物处方立法对改善他们的处方模式无效。总之,目前的数据表明,特雷维索地区绝大多数晚期癌症门诊患者在药物日剂量或治疗持续时间方面接受的阿片类药物处方不足。该地区全科医生对阿片类药物的误解可能导致这些镇痛药在癌症疼痛管理中使用不当。据我们所知,本次调查中用于阿片类药物处方分析的ATC/DDD方法此前尚未应用过。